secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001299130-22-000128
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio Q3 2022 revenue down 7% YoY to $32.3M; net loss $77M; withdraws guidance; launches Revio and Onso systems
--------------------------------------------------------------------------------

- Revenue $32.3M (down 7% YoY); instrument revenue $11.4M (down 28%); consumables revenue $16.1M (up 10%).
- GAAP net loss $77.0M ($0.34 EPS) vs net income $16.5M ($0.08 EPS) in Q3 2021; non-GAAP net loss $72.5M ($0.32 EPS).
- Cash and investments $834.3M, down from $1,044.4M at Dec 2021; withdrawn all prior financial guidance.
- Launched Revio long-read system (up to 1,300 human genomes/year, <$1k/genome) with shipments starting Q1 2023.
- Introduced Onso short-read system with 10x accuracy improvement; shipments expected H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/0001299130-22-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913022000128/pacb-20221103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001299130-22-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer